ONC
BeOne Medicines Ltd.
Key Financials
Operating Income
$447.1M
↑ 178.7%
Revenue
$5.3B
↑ 40.2%
Gross Profit
$4.7B
↑ 45.3%
Net Income
$286.9M
↑ 144.5%
EPS (Diluted)
$0.19
↑ 140.4%
Shareholders' Equity
$4.4B
↑ 30.9%
Total Assets
$8.2B
↑ 38.3%
Total Liabilities
$3.8B
↑ 47.9%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 3/A | 5/15/2026 | View on SEC |
| 4 | 5/15/2026 | View on SEC |
| 8-K | 5/15/2026 | View on SEC |
| SCHEDULE 13G/A | 5/14/2026 | View on SEC |
| 144 | 5/13/2026 | View on SEC |
| S-3ASR | 5/6/2026 | View on SEC |
| S-3ASR | 5/6/2026 | View on SEC |
| 10-Q | 5/6/2026 | View on SEC |
| 8-K | 5/6/2026 | View on SEC |
| ARS | 4/28/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ONC |
| Company Name | BeOne Medicines Ltd. |
| CIK | 1651308 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| Phone | 41-616851900 |